Ocqueteau M, Orfao A, García-Sanz R, Almeida J, Gonzalez M, San Miguel J F
Hospital Universitario de Salamanca, Spain.
Br J Haematol. 1996 Dec;95(3):489-93. doi: 10.1111/j.1365-2141.1996.tb08993.x.
The surface expression of CD117 on plasma cells (PCs) from normal individuals and patients with multiple myeloma (MM) has been analysed using triple-stained cells for flow cytometry. In addition, the clinical significance of CD117 expression in MM patients and its possible value for the evaluation of minimal residual disease was explored. A total of 11 healthy volunteers and 56 untreated MM patients were included in the study. The expression of CD117 was analysed by flow cytometry, using simultaneous staining with the MAbs BB4, CD117 and CD38. Cell acquisition was performed in two consecutive steps using a live gate drawn on SSC/CD38 cells and a total of 300,000 events were acquired. For data analysis, the Paint-a-Gate Plus software (Becton Dickinson) was used. PCs were identified according to their strong reactivity for CD38 and their positivity for BB4, as well as by their light scatter distribution. Dilution experiments of CD117+ myelomatous PCs with normal bone marrow (BM) cells were performed in order to assess the sensitivity level of the technique for detection of CD117+ residual PCs. None of the PCs from normal BM samples showed reactivity for the CD117 antigen. In contrast, CD117 antigen was present in 18/56 MM patients (32%), the proportion of positive cells in these cases being as high as 92.1 +/- 9%. Therefore, within PC lineage the c-Kit antigen would be restricted to the myelomatous population and thus could be considered as a 'tumour-associated marker' for monitoring minimal residual disease in about one third of MM patients. Dilution experiments indicate that the detection limit with this marker would be 10(-4) (one myelomatous PC/10(4) normal BM cells). Upon comparing the clinical and haematological disease characteristics of CD117-positive and CD117-negative cases, no significant differences were found.
采用三色染色细胞进行流式细胞术分析了正常个体和多发性骨髓瘤（MM）患者浆细胞（PC）上CD117的表面表达。此外，还探讨了CD117表达在MM患者中的临床意义及其在评估微小残留病方面的可能价值。该研究共纳入了11名健康志愿者和56例未经治疗的MM患者。通过流式细胞术分析CD117的表达，同时使用单克隆抗体BB4、CD117和CD38进行染色。使用在SSC/CD38细胞上绘制的活门分两个连续步骤进行细胞采集，共采集300,000个事件。数据分析使用Paint-a-Gate Plus软件（Becton Dickinson）。根据PC对CD38的强反应性、对BB4的阳性反应以及其光散射分布来鉴定PC。为了评估该技术检测CD117 +残留PC的灵敏度水平，进行了用正常骨髓（BM）细胞稀释CD117 +骨髓瘤PC的实验。正常BM样本中的PC均未显示对CD117抗原的反应性。相比之下，18/56例MM患者（32%）存在CD117抗原，这些病例中的阳性细胞比例高达92.1±9%。因此，在PC谱系中，c-Kit抗原将局限于骨髓瘤群体，因此可被视为约三分之一MM患者监测微小残留病的“肿瘤相关标志物”。稀释实验表明，该标志物的检测限为10^(-4)（1个骨髓瘤PC/10^4个正常BM细胞）。比较CD117阳性和CD117阴性病例的临床和血液学疾病特征，未发现显著差异。
